Earnings Feed
Start Free
Home/Filings/4/0001144204-16-084053
4//SEC Filing

CorMedix Inc. 4

Accession 0001144204-16-084053

$CRMDCIK 0001410098operating
View on SEC.govCompany Profile

Filed

Feb 23, 7:00 PM ET

Accepted

Feb 24, 4:35 PM ET

Size

18.3 KB

Accession

0001144204-16-084053

Insider Transaction Report

Form 4
Period: 2016-02-22
CorMedix Inc.CRMD
Duffy Matthew
Director
Transactions
  • Award

    Stock Option (right to buy)

    2016-02-22$1.91/sh+75,000$143,250→ 75,000 total
    Exercise: $1.91Exp: 2026-02-21→ Common Stock (75,000 underlying)
Holdings

  • Common Stock, $0.001 par value per share

    53,223

  • Stock Option (right to buy)

    Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (30,000 underlying)
    30,000

  • Stock Option (right to buy)

    Exercise: $0.90Exp: 2023-03-20→ Common Stock, $0.001 par value per share (100,000 underlying)
    100,000

  • Stock Option (right to buy)

    Exercise: $0.68Exp: 2022-12-05→ Common Stock, $0.001 par value per share (125,000 underlying)
    125,000

  • Warrant (right to purchase Common Stock)

    Exercise: $0.40From: 2012-11-13Exp: 2017-11-13→ Common Stock, $0.001 par value per share (25,000 underlying)
    25,000

  • Stock Option (right to buy)

    Exercise: $0.29Exp: 2022-01-06→ Common Stock, $0.001 par value per share (5,000 underlying)
    5,000

  • Stock Option (right to buy)

    Exercise: $0.28Exp: 2021-11-21→ Common Stock, $0.001 par value per share (15,000 underlying)
    15,000

  • Phantom Stock

    → Common Stock (594 underlying)
    594

  • Stock Option (right to buy)

    Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (150,000 underlying)
    150,000

  • Stock Option (right to buy)

    Exercise: $5.62Exp: 2025-03-01→ Common Stock, $0.001 par value per share (50,000 underlying)
    50,000
Footnotes (7)
  • [F1]These options vested 100% on January 10, 2014.
  • [F2]These options vest in full on the first anniversary of the date of grant.
  • [F3]These options vest quarterly over two years.
  • [F4]These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
  • [F5]On November 13, 2012, the reporting person acquired in a private placement $10,000 of (a) 9% Senior Convertible Notes, convertible into shares of the Company's common stock at a conversion price of $0.35 per share, and (b) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.
  • [F6]The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
  • [F7]Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a directo

Documents

1 file

Issuer

CorMedix Inc.

CIK 0001410098

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001410098

Filing Metadata

Form type
4
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 4:35 PM ET
Size
18.3 KB
View on SEC.gov